Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00454779 · ClinicalTrials.gov registry record · Phase 2
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
A Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 20
- Study locations
NCT00454779 is a Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck that has completed, run by Amgen. The registered enrollment target is 113 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT00454779, a Phase 2 study of Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent SCCHN.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Panitumumab
Study Locations (20)
California
- Research Site - Duarte
- Research Site - La Jolla
- Research Site - La Verne
- Research Site - Los Angeles
- Research Site - Santa Cruz
District of Columbia
- Research Site - Washington D.C.
- Research Site - Washington D.C.
- Research Site - Washington D.C.
- Research Site - Washington D.C.
Florida
- Research Site - Lakeland
- Research Site - Miami
- Research Site - New Port Richey
- Research Site - Orlando
Colorado
- Research Site - Aurora
- Research Site - Denver
Arizona
- Research Site - Tucson
Arkansas
- Research Site - Jonesboro
Connecticut
- Research Site - Norwich
Delaware
- Research Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2007-01-01 |
| Est. Completion | 2014-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00454779
The ClinicalTrials.gov registry entry for NCT00454779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT00454779 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT00454779 about?
NCT00454779 is a clinical study titled "PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response". This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over se...
What is the current status of trial NCT00454779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2007-01-01. Estimated completion is 2014-01-01.
What conditions does trial NCT00454779 study?
This clinical trial studies the following conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT00454779?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT00454779?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00454779 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.